Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHS Augmented With Cerament and Zoledronic Acid for Femur Fracture
NCT04498715Active, not recruiting
- Sponsor
- Lithuanian University of Health Sciences
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of zoledronic acid in intertrochanteric femoral fracture (2 arms), sponsored by Lithuanian University of Health Sciences. Primary endpoint: Change of bone density and remodeling around the head of dynamic screw at 6 months. Started Jun 2021; status: active, not recruiting.
02
Drugs
zoledronic acid
03
Conditions
intertrochanteric femoral fracture
Beyond the preview
Go deeper on NCT04498715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498715.